Enterprise Value
1.885M
Cash
9.956M
Avg Qtr Burn
-6.067M
Short % of Float
3.27%
Insider Ownership
2.31%
Institutional Own.
15.88%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
REQORSA (quaratusugene ozeplasmid) + Keytruda Details Non-small cell lung carcinoma, Cancer, Lung cancer | Phase 1/2 Update | |
REQORSA (quaratusugene ozeplasmid) + Tecentriq Details Cancer, Lung cancer, Small cell lung cancer | Phase 1/2 Initiation | |
REQORSA (quaratusugene ozeplasmid) + Tagrisso Details Non-small cell lung carcinoma, Lung cancer, Cancer | Phase 1/2 Initiation |